Teladoc Guides FY Revenue $2.36B-$2.45B, Below Consensus
TDOC sits 67% above its 52-week low of $4.4.
Summary
Teladoc Health issued FY revenue guidance of $2.36B-$2.45B, which falls short of the $2.58B consensus. The midpoint of $2.405B implies roughly flat growth year-over-year, a disappointment for a company that once commanded premium growth multiples. With shares at $7.36 and a market cap near $1.66B, the guidance signals continued demand headwinds in the virtual care space. No specific catalysts are on the immediate horizon, but the next earnings call will be critical for management to address the growth trajectory.
At the time of this announcement, TDOC was trading at $7.36 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $4.40 to $9.89. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.